Cargando…

Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts

Cannabidiol (CBD) is a non-intoxicating phytocannabinoid from cannabis sativa that has demonstrated anti-inflammatory effects in several inflammatory conditions including arthritis. However, CBD binds to several receptors and enzymes and, therefore, its mode of action remains elusive. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowin, Torsten, Tingting, Ren, Zurmahr, Julia, Classen, Tim, Schneider, Matthias, Pongratz, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463000/
https://www.ncbi.nlm.nih.gov/pubmed/32873774
http://dx.doi.org/10.1038/s41419-020-02892-1
_version_ 1783577034973249536
author Lowin, Torsten
Tingting, Ren
Zurmahr, Julia
Classen, Tim
Schneider, Matthias
Pongratz, Georg
author_facet Lowin, Torsten
Tingting, Ren
Zurmahr, Julia
Classen, Tim
Schneider, Matthias
Pongratz, Georg
author_sort Lowin, Torsten
collection PubMed
description Cannabidiol (CBD) is a non-intoxicating phytocannabinoid from cannabis sativa that has demonstrated anti-inflammatory effects in several inflammatory conditions including arthritis. However, CBD binds to several receptors and enzymes and, therefore, its mode of action remains elusive. In this study, we show that CBD increases intracellular calcium levels, reduces cell viability and IL-6/IL-8/MMP-3 production of rheumatoid arthritis synovial fibroblasts (RASF). These effects were pronounced under inflammatory conditions by activating transient receptor potential ankyrin (TRPA1), and by opening of the mitochondrial permeability transition pore. Changes in intracellular calcium and cell viability were determined by using the fluorescent dyes Cal-520/PoPo3 together with cell titer blue and the luminescent dye RealTime-glo. Cell-based impedance measurements were conducted with the XCELLigence system and TRPA1 protein was detected by flow cytometry. Cytokine production was evaluated by ELISA. CBD reduced cell viability, proliferation, and IL-6/IL-8 production of RASF. Moreover, CBD increased intracellular calcium and uptake of the cationic viability dye PoPo3 in RASF, which was enhanced by pre-treatment with TNF. Concomitant incubation of CBD with the TRPA1 antagonist A967079 but not the TRPV1 antagonist capsazepine reduced the effects of CBD on calcium and PoPo3 uptake. In addition, an inhibitor of the mitochondrial permeability transition pore, cyclosporin A, also blocked the effects of CBD on cell viability and IL-8 production. PoPo3 uptake was inhibited by the voltage-dependent anion-selective channel inhibitor DIDS and Decynium-22, an inhibitor for all organic cation transporter isoforms. CBD increases intracellular calcium levels, reduces cell viability, and IL-6/IL-8/MMP-3 production of RASF by activating TRPA1 and mitochondrial targets. This effect was enhanced by pre-treatment with TNF suggesting that CBD preferentially targets activated, pro-inflammatory RASF. Thus, CBD possesses anti-arthritic activity and might ameliorate arthritis via targeting synovial fibroblasts under inflammatory conditions.
format Online
Article
Text
id pubmed-7463000
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74630002020-09-11 Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts Lowin, Torsten Tingting, Ren Zurmahr, Julia Classen, Tim Schneider, Matthias Pongratz, Georg Cell Death Dis Article Cannabidiol (CBD) is a non-intoxicating phytocannabinoid from cannabis sativa that has demonstrated anti-inflammatory effects in several inflammatory conditions including arthritis. However, CBD binds to several receptors and enzymes and, therefore, its mode of action remains elusive. In this study, we show that CBD increases intracellular calcium levels, reduces cell viability and IL-6/IL-8/MMP-3 production of rheumatoid arthritis synovial fibroblasts (RASF). These effects were pronounced under inflammatory conditions by activating transient receptor potential ankyrin (TRPA1), and by opening of the mitochondrial permeability transition pore. Changes in intracellular calcium and cell viability were determined by using the fluorescent dyes Cal-520/PoPo3 together with cell titer blue and the luminescent dye RealTime-glo. Cell-based impedance measurements were conducted with the XCELLigence system and TRPA1 protein was detected by flow cytometry. Cytokine production was evaluated by ELISA. CBD reduced cell viability, proliferation, and IL-6/IL-8 production of RASF. Moreover, CBD increased intracellular calcium and uptake of the cationic viability dye PoPo3 in RASF, which was enhanced by pre-treatment with TNF. Concomitant incubation of CBD with the TRPA1 antagonist A967079 but not the TRPV1 antagonist capsazepine reduced the effects of CBD on calcium and PoPo3 uptake. In addition, an inhibitor of the mitochondrial permeability transition pore, cyclosporin A, also blocked the effects of CBD on cell viability and IL-8 production. PoPo3 uptake was inhibited by the voltage-dependent anion-selective channel inhibitor DIDS and Decynium-22, an inhibitor for all organic cation transporter isoforms. CBD increases intracellular calcium levels, reduces cell viability, and IL-6/IL-8/MMP-3 production of RASF by activating TRPA1 and mitochondrial targets. This effect was enhanced by pre-treatment with TNF suggesting that CBD preferentially targets activated, pro-inflammatory RASF. Thus, CBD possesses anti-arthritic activity and might ameliorate arthritis via targeting synovial fibroblasts under inflammatory conditions. Nature Publishing Group UK 2020-09-01 /pmc/articles/PMC7463000/ /pubmed/32873774 http://dx.doi.org/10.1038/s41419-020-02892-1 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lowin, Torsten
Tingting, Ren
Zurmahr, Julia
Classen, Tim
Schneider, Matthias
Pongratz, Georg
Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts
title Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts
title_full Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts
title_fullStr Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts
title_full_unstemmed Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts
title_short Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts
title_sort cannabidiol (cbd): a killer for inflammatory rheumatoid arthritis synovial fibroblasts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463000/
https://www.ncbi.nlm.nih.gov/pubmed/32873774
http://dx.doi.org/10.1038/s41419-020-02892-1
work_keys_str_mv AT lowintorsten cannabidiolcbdakillerforinflammatoryrheumatoidarthritissynovialfibroblasts
AT tingtingren cannabidiolcbdakillerforinflammatoryrheumatoidarthritissynovialfibroblasts
AT zurmahrjulia cannabidiolcbdakillerforinflammatoryrheumatoidarthritissynovialfibroblasts
AT classentim cannabidiolcbdakillerforinflammatoryrheumatoidarthritissynovialfibroblasts
AT schneidermatthias cannabidiolcbdakillerforinflammatoryrheumatoidarthritissynovialfibroblasts
AT pongratzgeorg cannabidiolcbdakillerforinflammatoryrheumatoidarthritissynovialfibroblasts